Publicaciones en las que colabora con José Martínez Lanao (59)

2009

  1. Evaluation of population pharmacokinetic models for amikacin dosage individualization in critically ill patients

    Journal of Pharmacy and Pharmacology, Vol. 61, Núm. 6, pp. 759-766

2004

  1. Pharmacokinetic basis for the use of extended interval dosage regimens of gentamicin in neonates

    Journal of Antimicrobial Chemotherapy, Vol. 54, Núm. 1, pp. 193-198

1999

  1. Population pharmacokinetics of amikacin in patients with haematological malignancies

    Journal of Antimicrobial Chemotherapy, Vol. 44, Núm. 2, pp. 235-242

1998

  1. Influence of clinical diagnosis in the population pharmacokinetics of amikacin in intensive care unit patients

    Clinical Drug Investigation, Vol. 15, Núm. 5, pp. 435-444

1997

  1. Population pharmacokinetics of caffeine in premature neonates

    European Journal of Clinical Pharmacology, Vol. 52, Núm. 3, pp. 211-217

  2. Study on pharmacokinetics and nephrotoxicity of netilmicin in rabbits using a new dosage regimen

    Methods and Findings in Experimental and Clinical Pharmacology, Vol. 19, Núm. 1, pp. 53-59

1996

  1. Bayesian forecasting in paediatric populations

    Clinical Pharmacokinetics

  2. Influence of pharmacokinetic model on vancomycin peak concentration targets

    Therapeutic Drug Monitoring, Vol. 18, Núm. 2, pp. 145-148

  3. Pharmacokinetics of amikacin in intensive care unit patients

    Journal of Clinical Pharmacy and Therapeutics, Vol. 21, Núm. 6, pp. 417-421

1995

  1. Binding of roxithromycin to total plasma proteins, albumin, polymorphonuclear cells and lymphocytes

    Revista Espanola de Quimioterapia, Vol. 8, Núm. 1, pp. 46-50

  2. Determination of netilmicin in plasma by HPLC

    Journal of Pharmaceutical and Biomedical Analysis, Vol. 13, Núm. 8, pp. 1059-1062

  3. Uptake of antibiotics by phagocytic cells: Study methods and therapeutic implications

    Revista Espanola de Quimioterapia, Vol. 8, Núm. 2, pp. 100-108

1992

  1. A method for the calculation of bioavailability in slow release formulations in the presence of within-individual variability

    International Journal of Pharmaceutics, Vol. 86, Núm. 2-3, pp. 123-130

  2. LIMITACIONES ANALITICAS EN LA MONITORIZACION DE NIVELES SERICOS DE DIGOXINA

    Farmacia Clinica, Vol. 9, Núm. 9, pp. 774-785

1991

  1. Bioequivalence of a new formulation of flecainide acetate.

    European journal of drug metabolism and pharmacokinetics, Vol. Spec No 3, pp. 216-220

1990

  1. Effect of renal impairment on distribution of ofloxacin

    Antimicrobial Agents and Chemotherapy, Vol. 34, Núm. 3, pp. 455-459

  2. Evolución histórica de la biofarmacia y farmacocinética, una nueva disciplina farmacéutica

    Industria farmacéutica: Equipos, procesos y tecnología, Núm. 2, pp. 151-156

  3. Influence of a single dose of ethanol on the kinetics of valproic acid in rats

    Drug Metabolism and Disposition, Vol. 18, Núm. 5, pp. 732-734

  4. Optimization of dosage regimens of aminoglycoside antibiotics in the presence of beta-lactam agents by simulation techniques

    Acta Pharmaceutica Jugoslavica, Vol. 40, Núm. 2 SUPPL. 1, pp. 301-308

1989

  1. MODIFICACIONES EN LA CINETICA DEL CLOBAZAM EN MODELO EXPERIMENTAL DE ALCOHOLISMO CRONICO

    Ciencia e Industria Farmaceutica, Vol. 8, Núm. 10-12, pp. 238-241